Study guide

5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

ASCP Hematology Technologist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Hematopoiesis & Cellular Physiology

1.1 Hematopoiesis, Bone Marrow Microenvironment & Growth Factors 1.2 Erythrocyte Physiology, Metabolism & Destruction Pathways 1.3 Leukocyte Kinetics, Morphology & Phagocytic Function 1.4 Platelet Physiology, Ultrastructure & Thrombopoiesis

2 Chapter 2: Erythrocyte Disorders & Non-Hemolytic Anemias

2.1 Iron Metabolism & Iron Deficiency Anemia 2.2 Anemia of Chronic Inflammation, Sideroblastic Anemias & Lead Toxicity 2.3 Hemoglobinopathies & Qualitative Globin Chain Defects 2.4 Alpha and Beta Thalassemias 2.5 Megaloblastic, Macrocytic & Hypoproliferative Anemias

3 Chapter 3: Hemolytic Anemias & Erythrocytosis

3.1 Intrinsic Hemolytic Anemias: Membrane & Metabolic Defects 3.2 Immune-Mediated Hemolytic Anemias & Paroxysmal Nocturnal Hemoglobinuria 3.3 Non-Immune Extrinsic Hemolytic Anemias & Microangiopathies 3.4 Polycythemia & Erythrocytosis Classification

4 Chapter 4: Benign Leukocyte Alterations, Acute Leukemias & Bone Marrow Evaluation

4.1 Quantitative Leukocyte Alterations, Toxic Change & Leukemoid Reaction 4.2 Inherited Leukocyte Anomalies, Reactive Lymphocytosis & Storage Disorders 4.3 Acute Myeloid Leukemia (AML) & Related Neoplasms 4.4 Acute Lymphoblastic Leukemia (ALL) & Precursor Lymphoid Neoplasms 4.5 Bone Marrow Examination, Differential & M:E Ratio Assessment

5 Chapter 5: Chronic Myeloid Neoplasms, MDS & Mature Lymphoid Neoplasms

5.1 Myelodysplastic Syndromes (MDS) & Overlap Syndromes 5.2 Chronic Myeloproliferative Neoplasms (CML, PV, ET, PMF) 5.3 Chronic Lymphocytic Leukemia & Indolent B-Cell Lymphomas 5.4 Aggressive Lymphomas, Hodgkin Lymphoma & Mature T-Cell Disorders 5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

6 Chapter 6: Hemostasis: Primary, Secondary & Fibrinolytic Systems

6.1 Primary Hemostasis, Platelet Receptors & Qualitative Platelet Disorders 6.2 Quantitative Platelet Disorders & Immune Thrombocytopenias 6.3 The Coagulation Cascade & Cell-Based Hemostatic Model 6.4 Fibrinolytic System, Natural Anticoagulants & Thrombophilia

7 Chapter 7: Factor Deficiencies, Coagulation Testing & Anticoagulation

7.1 Hereditary Coagulation Factor Deficiencies & von Willebrand Disease 7.2 Acquired Coagulation Factor Deficiencies, Circulating Inhibitors & DIC 7.3 Routine and Specialized Coagulation Testing & Mixing Study Interpretation 7.4 Anticoagulant Therapies, Laboratory Monitoring & Reversal Strategies 7.5 Viscoelastic Testing, Heparin Neutralization & Chromogenic Assays

8 Chapter 8: Hematology Laboratory Testing & Advanced Diagnostics

8.1 Automated Hematology Analyzers, Interference Flags & Manual Methods 8.2 Cytochemical Staining, Flow Cytometry & Molecular Diagnostics 8.3 Erythrocyte Sedimentation Rate, Hemolytic Indicators & Special Erythrocyte Studies 8.4 Cerebrospinal Fluid Analysis, Cell Counts & Cytology 8.5 Serous Effusions & Synovial Fluid Analysis

9 Chapter 9: Laboratory Operations, Quality Assessment & Safety

9.1 The Total Testing Process: Preanalytical, Analytical & Postanalytical Quality 9.2 Quality Control Statistics, Levey-Jennings Charts & Westgard Multirules 9.3 Laboratory Mathematics: Dilutions, Concentration, Molarity & Standard Curves 9.4 Method Evaluation, Diagnostic Statistics & Point-of-Care Testing 9.5 Regulatory Framework, Proficiency Testing & Competency Assessment 9.6 Laboratory Safety: Bloodborne Pathogens, Personal Protective Equipment & Chemical Hygiene 9.7 Emergency Response, Spill Management & Specimen Packaging and Transport 9.8 Hematology Instrumentation: Microscopy, Counters, Analyzers & Centrifuges

5.5 Plasma Cell Neoplasms & Monoclonal Gammopathies

Key Takeaways Explain This Topic AI

Multiple myeloma requires at least 10% clonal marrow plasma cells (or a plasmacytoma) plus CRAB end-organ damage: hyperCalcemia, Renal insufficiency, Anemia, and lytic Bone lesions.

Monoclonal gammopathy of undetermined significance requires all three of an M-spike below 3.0 g/dL, clonal plasma cells below 10%, and no CRAB damage, and progresses to myeloma at roughly 1% per year.

Neoplastic myeloma plasma cells are CD138 positive, CD38 bright, aberrantly CD56 positive, and CD19 NEGATIVE, with cytoplasmic light chain restriction confirming clonality.

Rouleaux from a high paraprotein is dispersed by saline replacement, whereas true red cell agglutination from a cold agglutinin is not; this bedside distinction is a recurring examination item.

Waldenstrom macroglobulinemia produces a pentameric IgM paraprotein with hyperviscosity and the MYD88 L265P mutation, and characteristically LACKS the lytic bone lesions of multiple myeloma.

Last updated: August 2026

Plasma Cell Neoplasms & Monoclonal Gammopathies

Plasma cell dyscrasias are listed by the ASCP BOC as a distinct lymphoid neoplasia sub-topic. They reach the hematology bench in three ways: as an unexplained rouleaux formation and a markedly elevated erythrocyte sedimentation rate on a routine smear, as a background staining abnormality that interferes with automated counts, and as marrow plasmacytosis on aspirate differential. The examination expects the diagnostic thresholds that separate a monoclonal gammopathy of undetermined significance from smoldering and symptomatic myeloma.

Plasma cell dyscrasias represent monoclonal proliferations of terminal B-lineage effector cells (plasma cells) that secrete a single, homogeneous monoclonal immunoglobulin or free light chain ( M-protein / paraprotein ). SPEP / UPEP ELECTROPHORESIS PROFILE

  • Albumin α1 α2 β γ (Gamma Region)
  • ┌───┐ │
  • │ │ ┌─┴─┐
  • │ │ │ M │ ◄── Monoclonal M-Spike (IgG/IgA/IgM)
  • │ │ │ │ (Sharp, narrow, dense band)
  • │ │ ┌─┐ ┌───┐ ┌───┐ │ │
  • │ │ │ │ │ │ │ │ │ │
  • ──┴───┴────┴─┴────┴───┴────┴───┴────────┴───┴───────────────────────────────
  • A. Multiple Myeloma (MM)

Multiple Myeloma is a malignant neoplasm of terminally differentiated plasma cells accounting for ~10% of hematologic malignancies (median age ~69 years; more common in African Americans and males).

Diagnostic Criteria & CRAB Features

Diagnosis requires ≥ 10 % \ge 10\% ≥ 10% clonal bone marrow plasma cells (or biopsy-proven plasmacytoma) PLUS at least one CRAB end-organ damage criterion (or a SLiM biomarker of malignancy: ≥ 60 % \ge 60\% ≥ 60% marrow plasma cells, serum free light chain ratio ≥ 100 \ge 100 ≥ 100 , or > 1 >1 > 1 focal lesion on MRI):

C — Hypercalcemia : Serum calcium > 11.0 mg/dL >11.0\text{ mg/dL} > 11.0 mg/dL (due to osteoclast-mediated bone resorption).

R — Renal Insufficiency : Serum creatinine > 2.0 mg/dL >2.0\text{ mg/dL} > 2.0 mg/dL or creatinine clearance < 40 mL/min <40\text{ mL/min} < 40 mL/min (caused by myeloma cast nephropathy : excess monoclonal free light chains precipitate with Tamm-Horsfall mucoprotein in distal renal tubules).

A — Anemia : Normocytic, normochromic anemia ( Hb < 10.0 g/dL \text{Hb} < 10.0\text{ g/dL} Hb < 10.0 g/dL or > 2.0 g/dL >2.0\text{ g/dL} > 2.0 g/dL below normal) from bone marrow replacement and cytokine suppression.

B — Bone Lesions : Multiple "punched-out" osteolytic bone lesions, severe osteopenia, or pathologic fractures on skeletal surveys, CT, or MRI (driven by plasma cell secretion of RANKL and DKK1, which activate osteoclasts and suppress osteoblasts). MULTIPLE MYELOMA CRAB PATHOLOGY

  • [C] Hypercalcemia ──► Bone resorption from RANKL osteoclast activation
  • [R] Renal Failure ──► Light chain cast nephropathy (Bence Jones proteinuria)
  • [A] Anemia ──► Marrow replacement & cytokine-induced erythropoietin resistance
  • [B] Bone Lytic Lesions ──► "Punched-out" skull/axial skeleton lesions & pathologic fractures
  • Peripheral Blood Smear & The Saline Replacement Technique

Rouleaux Formation : High concentrations of cationic circulating paraproteins (M-protein) neutralize the negative sialic acid surface charge ( zeta potential ) of erythrocytes, causing red cells to aggregate and stack face-to-face like rolls of coins .

Laboratory Differentiation (Rouleaux vs. Agglutination) : True antigen-antibody cold agglutination (e.g., Cold Agglutinin Disease) forms irregular, clumped grape-like clusters, whereas rouleaux forms linear stacks. To differentiate:

Centrifuge the sample and replace the plasma with an equal volume of 0.85% isotonic saline ( Saline Replacement Technique ).

Result : Saline disperses rouleaux completely, whereas true antibody-mediated agglutination persists despite saline dilution.

Plasma Cell Cytology : Malignant plasma cells display eccentric round nuclei, condensed "clock-face" or "cartwheel" chromatin , abundant deep royal-blue cytoplasm, and a prominent pale perinuclear halo (Golgi apparatus) .

Mott Cells (Grape / Morular Cells) : Plasma cells packed with clear, spherical cytoplasmic inclusions containing accumulated immunoglobulin ( Russell bodies inside cytoplasm; Dutcher bodies inside the nucleus).

Flame Cells : Plasma cells with bright vermilion/pink-red margins, classically associated with IgA myeloma .

Laboratory Diagnostics & Immunophenotype

Serum & Urine Protein Electrophoresis (SPEP / UPEP) : Demonstrates a sharp, narrow, symmetric M-spike in the gamma or beta globulin region (monoclonal isotypes: IgG ~55% , IgA ~20% , Light chain only ~15–20% , IgD/IgE < 2 % <2\% < 2% ).

Bence Jones Protein : Monoclonal free kappa or lambda light chains in urine that precipitate between 56 ∘ C 56^\circ\text{C} 5 6 ∘ C and 60 ∘ C 60^\circ\text{C} 6 0 ∘ C and redissolve upon boiling at 100 ∘ C 100^\circ\text{C} 10 0 ∘ C .

Diagnostic Flow Cytometry : Neoplastic plasma cells are CD138+ (Syndecan-1) , CD38+ (bright) , CD56+ (aberrant NCAM expression) , CD117+ , with monoclonal cytoplasmic light chain restriction ( κ \kappa κ or λ \lambda λ ). Malignant plasma cells are characteristically CD19 NEGATIVE and CD45 NEGATIVE (distinguishing them from normal reactive plasma cells, which are CD19+CD45+CD56-).

B. Monoclonal Gammopathy of Undetermined Significance (MGUS)

Diagnostic Thresholds : Serum M-protein < 3.0 g/dL <3.0\text{ g/dL} < 3.0 g/dL , clonal bone marrow plasma cells < 10 % <10\% < 10% , and complete absence of CRAB end-organ damage or amyloidosis.

Progression : Carries an obligatory lifelong risk of progression to overt Multiple Myeloma at a rate of approximately 1 % 1\% 1% per year .

C. Waldenström Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma

Definition : Clonal neoplasm of small lymphocytes, plasmacytoid lymphocytes, and plasma cells in the bone marrow that secrete a monoclonal IgM paraprotein .

Pathognomonic Genetics : Somatic M Y D 88 MYD88 M Y D 88 L265P mutation is present in > 90 – 95 % >90\text{--}95\% > 90 – 95% of cases (causing continuous downstream TLR-IRAK-NF- κ \kappa κ B signaling).

Clinical Hallmark : Hyperviscosity Syndrome caused by the large, pentameric structure of IgM ( 970 kDa 970\text{ kDa} 970 kDa ). Manifests with visual blurring, "sausage-link" retinal vein dilation, retinal hemorrhages, epistaxis, dizziness, and headaches. Unlike myeloma, lytic bone lesions and hypercalcemia are absent .

Loading diagram... Diagnostic Separation of Plasma Cell Neoplasms and Monoclonal Gammopathies